A phase II study of 5-Fluorcuracil, cisplatin, and 4'-Epirubicin in the treatment of advanced solid cancers

Y. Nio, C. C. Tseng, T. Shiraishi, M. Tsubono, K. Kawabata, Y. Masai, H. Hayashi, M. Fukumoto, M. Nio, M. Sato, J. Mizuta, T. Tobe

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

This phase II study was designed to assess the therapeutic potential of intensive course treatment with three anticancer agents: 50 mg of cisplatin on day 1, 40 mg/m2 of epirubicin on day 2, and 250 mg of 5-fluorouracil on days 2 through 5. Drug courses were repeated every 2 weeks and most patients received between 4 and 6 courses. Thirty-five patients with measurable advanced solid cancers entered the study. They consisted of 16 gastric, 5 colorectal, 4 gallbladder, 3 pancreatic, 3 lung, 2 esophageal, 1 uterine, and 1 ovarian cancers. Of the 35 patients, 29 were evaluated for therapeutic effect of the regimen, and the overall response rate was 31.0% (5 CR + 4 PR/29). A 33.3% rate of tumor regression, consisting of 2 complete responses (CR) and 3 partial responses (PR) out of 15 patients (2 CR + 3 PR/15), was seen for gastric cancers. For the other types of tumors the responses were achieved in 2 lung cancers (1 CR + 1 PR/3), 1 uterine cancer (1 CR/1), and 1 ovarian cancer (1 CR/1). The esophageal, colorectal, pancreatic, and gallbladder cancers were unresponsive to this regimen. Toxicities of the drug treatment were clinically tolerable and consisted of general malaise, nausea, vomiting, stomatitis, alopecia, and leucopenia. However, two patients died of uncontrollable metabolic acidosis after 1 and 2 courses, respectively. This intensive course treatment appears to promote the regression of gastric, lung, and gynecologic cancers.

Original languageEnglish
Pages (from-to)96-101
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number2
DOIs
Publication statusPublished - 1993 Jan 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of 5-Fluorcuracil, cisplatin, and 4'-Epirubicin in the treatment of advanced solid cancers'. Together they form a unique fingerprint.

Cite this